Cboe UK EUR

Dermapharm Holding SE (DMPD.XC)

38.88
0.00
(0.00%)
At close: February 25 at 4:03:30 PM GMT
Loading Chart for DMPD.XC
  • Previous Close 38.88
  • Open 38.88
  • Bid 43.78 x --
  • Ask 44.58 x --
  • Day's Range 38.88 - 38.88
  • 52 Week Range 38.88 - 47.97
  • Volume 35
  • Avg. Volume 0
  • Market Cap (intraday) 2.093B
  • Beta (5Y Monthly) 1.28
  • PE Ratio (TTM) 20.25
  • EPS (TTM) 1.92
  • Earnings Date Aug 26, 2025
  • Forward Dividend & Yield 0.90 (2.32%)
  • Ex-Dividend Date Jun 27, 2025
  • 1y Target Est --

Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.

ir.dermapharm.de

3,610

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DMPD.XC

View More

Performance Overview: DMPD.XC

Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

DMPD.XC
18.96%
DAX P (^GDAXI)
18.12%

1-Year Return

DMPD.XC
17.45%
DAX P (^GDAXI)
28.75%

3-Year Return

DMPD.XC
19.90%
DAX P (^GDAXI)
75.14%

5-Year Return

DMPD.XC
0.31%
DAX P (^GDAXI)
96.80%

Compare To: DMPD.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DMPD.XC

View More

Valuation Measures

Annual
As of 6/13/2025
  • Market Cap

    1.95B

  • Enterprise Value

    2.81B

  • Trailing P/E

    20.25

  • Forward P/E

    16.21

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.77

  • Price/Book (mrq)

    3.28

  • Enterprise Value/Revenue

    2.32

  • Enterprise Value/EBITDA

    9.03

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.64%

  • Return on Assets (ttm)

    6.40%

  • Return on Equity (ttm)

    16.57%

  • Revenue (ttm)

    1.2B

  • Net Income Avi to Common (ttm)

    103.57M

  • Diluted EPS (ttm)

    1.92

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    115.18M

  • Total Debt/Equity (mrq)

    154.98%

  • Levered Free Cash Flow (ttm)

    79.2M

Research Analysis: DMPD.XC

View More

Company Insights: DMPD.XC

Research Reports: DMPD.XC

View More